2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)
Status:
Withdrawn
Trial end date:
2020-07-08
Target enrollment:
Participant gender:
Summary
This study will evaluate the ability of Expanded Natural Killer (ENK) cells to treat multiple
myeloma when administered as part of a regimen consisting of Elotuzumab and a stem cell
transplant. Natural killer cells are a special type of white blood cells that are already
present in the body which have the ability to kill myeloma cells. In this study, natural
killer cells will be collected and then treated in a laboratory to activate and 'expand' the
number of cells to increase the dose and the anti-myeloma activity of the cells before they
are transfused back into the subject. Elotuzumab is a protein drug approved by the United
States Food and Drug Administration (FDA) for patients with previously treated multiple
myeloma and works by activating natural killer cells already present in the body and
targeting a protein called SLAMF7 which is present on both natural killer cells and myeloma
cells. The investigators hope that administering Elotuzumab in combination with ENK cells
will enhance the anti-myeloma activity of the ENK cells.
Phase:
Phase 2
Details
Lead Sponsor:
University of Arkansas
Collaborators:
Altor BioScience Altor Bioscience Corporation Bristol-Myers Squibb